Clinical Trials
36 trialsNCT05169515 2026-05-18
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1 Recruiting
NCT07594067 2026-05-18
TCR1188-ABC Cells in KRAS-mutated Cancers
University of Pennsylvania
Phase 1 Not yet recruiting
NCT05646836 2026-05-14
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Genentech, Inc.
Phase 1 Active not recruiting
NCT06934044 2026-05-11
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche
Phase 1 Recruiting
NCT05091424 2026-05-04
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 1 Recruiting
NCT05927571 2026-05-04
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Genentech, Inc.
Phase 1 Recruiting
NCT06624085 2026-05-04
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Recruiting
NCT04910568 2026-03-19
CAMMA 1
Genentech, Inc.
Phase 1 Active not recruiting
NCT03448042 2026-02-27
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Genentech, Inc.
Phase 1 Active not recruiting
NCT05391750 2026-02-17
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
Emory University
Phase 1 Active not recruiting
NCT03275103 2026-02-05
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Genentech, Inc.
Phase 1 Completed
NCT04616248 2026-01-07
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT05364424 2025-12-01
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed
NCT04007029 2025-09-05
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06016179 2025-05-22
RIOT2
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 1 Recruiting
NCT05619744 2025-03-10
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Hoffmann-La Roche
Phase 1 Completed
NCT03467373 2025-01-17
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
Hoffmann-La Roche
Phase 1 Completed
NCT04338685 2024-12-09
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Hoffmann-La Roche
Phase 1 Completed
NCT06372574 2024-09-03
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
Genentech, Inc.
Phase 1 Withdrawn
NCT05333302 2024-08-28
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Phase 1 Recruiting
NCT05219513 2024-08-23
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 1 Terminated
NCT03866239 2024-08-09
A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
Hoffmann-La Roche
Phase 1 Terminated
NCT05769959 2024-07-09
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT04580121 2024-06-03
A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
Hoffmann-La Roche
Phase 1 Completed
NCT04313608 2024-03-25
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed
NCT04657302 2024-01-19
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed
NCT05129280 2023-08-04
A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT04547062 2023-04-28
Tocilam
Nantes University Hospital
Phase 1 Completed
NCT04551352 2022-10-03
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
Hoffmann-La Roche
Phase 1 Completed
NCT03588936 2021-10-11
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Medical College of Wisconsin
Phase 1 Terminated
NCT03135171 2021-09-10
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT02906371 2021-07-02
Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
University of Pennsylvania
Phase 1 Completed
NCT02336048 2021-04-08
A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities
Hoffmann-La Roche
Phase 1 Terminated
NCT03539484 2020-09-03
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT02324257 2020-04-17
A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02057770 2018-10-12
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Washington University School of Medicine
Phase 1 Terminated